Contents

Search

antihemophilic factor (coagulation factor VIII, AHF-M, Hemofil, Humate-P, Monoclate-P)

Tradenames: AHF-M, Hemofil, Humate-P, Monoclate-P, Advate* Indications: - management of hemophilia A Contraindications: - hypersensitivity to mouse proteins (preparation contains trace amounts of mouse protein* Pregnancy category: C) Safety in lactation: ? Dosage: 1) individualize dose based upon coagulation studies 2) one unit will increase circulating AHF by 2% 3) hospitalized patients: a) 20-50 units/kg/dose b) may be given every 12-24 hours & more frequently in special circumstances AHF units = body weight (kg) x desired AHF increase (%) x 0.5 * Advate (Baxter) is free of plasma & albumin [5] Pharmacokinetics: - elimination: liver - elimination 1/2life 4-24 hours (biphasic) Adverse effects: - uncommon (< 1%) - flushing, tachycardia, headache, nausea/vomiting, paresthesia, allergic vasomotor reactions, tightness in neck or chest

Related

coagulation cascade coagulation factor VIII autoantibody (acquired hemophilia) coagulation factor VIIIa von Willebrand factor; vWF; ristocetin cofactor; factor VIII related antigen; contains: von Willebrand antigen 2 (VWF, F8VWF)

Specific

recombinant factor VIII; turoctocog alfa; (Factorate, Recombinate, Xyntha, Kogenate FS, Kovaltry, NovoEight)

General

coagulation factor VIII; antihemophilic factor; AHF; procoagulant component; contains: factor VIIIa heavy chain, 200 kD & 92 isoforms; factor VIII B chain; factor VIIIa light chain (F8, F8C) hematologic agent

References

  1. Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. FASEB J. 1992 May;6(8):2561-7. Review. PMID: 1317308
  2. Andrews BS. Is the WKS motif the tissue-factor binding site for coagulation factor VII? Trends Biochem Sci. 1991 Jan;16(1):31-6. Review. PMID: 2053135
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. Medical Knowledge Self Assessment Program (MKSAP) 11, 18. American College of Physicians, Philadelphia 1998, 2018,
  5. Prescriber's Letter 11(2):suppl 2004
  6. Department of Veterans Affairs, VA National Formulary

Component-of

antihemophilic factor/von willebrand factor